Regulus Therapeutics Inc. | Mutual Funds
Mutual Funds that own Regulus Therapeutics Inc.
Fidelity Select Biotechnology Portfolio
4,440,151
4.24%
0
0.01%
07/31/2018
Vanguard Total Stock Market Index Fund
2,078,501
1.98%
0
0%
07/31/2018
Fidelity Growth Company Fund
1,976,188
1.89%
-3,260,328
0%
07/31/2018
Fidelity Series Growth Company Fund
640,927
0.61%
-867,905
0%
07/31/2018
Rhenman & Partners Fund - Healthcare Equity L/S
492,878
0.47%
-100,751
0.01%
12/31/2017
FCP OP Medical BioHe@lth-Trends
438,392
0.42%
0
0.06%
11/30/2017
Vanguard Extended Market Index Fund
390,039
0.37%
1,100
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
368,835
0.35%
0
0%
07/31/2018
APO Medical Opportunities
204,733
0.2%
-35,883
0.01%
03/31/2018
Vanguard Institutional Total Stock Market Index Fund
88,514
0.08%
0
0%
07/31/2018
| Address |
10628 Science Center Drive
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.regulusrx.com |
| Updated |
07/08/2019 |
| Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. |
